BridgeMD
New treatment option for Rotator Cuff Tendinopathy
Official title Tight Control for Rotator Cuff Tendinopathy
ClinicalTrials.gov ID: NCT06517680
What this study is testing
- What it's testing
- The main objective of the study is to determine whether tight management of patients in early rotator cuff tendinopathy would lead to better clinical improvement than standard management. In a randomized study, we propose to compare two types of management, with a tight control group having one consultation per month for the first 3 months, in order to readapt or intensify management, whereas the control group will only be seen at 3 months after inclusion.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Patient with new-onset shoulder pain related to rotator cuff tendinopathy
- Age between 18 and 65
- Shoulder pain on activity for less than 6 months with VAS≥4/10 and/or OSS≥20
- Pain compatible with rotator cuff tendinopathy according to the rotator cuff tendinopathy according to the BESS (British Elbow and Shoulder Society)...
You likely can't join if
- Contraindication to steroid injections
- Shoulder pain related to trauma (dislocation, fracture) or acute tendon rupture requiring short-term surgery
- Steroid injection already performed on the shoulder studied for the current episode
- Neurological pathology affecting the shoulder
- Other shoulder disorders (inflammatory arthritis, frozen shoulder, glenohumeral joint instability, pain associated with acromioclavicular arthropathy)
- Tendon calcification \> 0.5 cm.
See the full eligibility criteria
- Patient with new-onset shoulder pain related to rotator cuff tendinopathy
- Age between 18 and 65
- Shoulder pain on activity for less than 6 months with VAS≥4/10 and/or OSS≥20
- Pain compatible with rotator cuff tendinopathy according to the rotator cuff tendinopathy according to the BESS (British Elbow and Shoulder Society) guidelines
- Contraindication to steroid injections
- Shoulder pain related to trauma (dislocation, fracture) or acute tendon rupture requiring short-term surgery
- Steroid injection already performed on the shoulder studied for the current episode
- Neurological pathology affecting the shoulder
- Other shoulder disorders (inflammatory arthritis, frozen shoulder, glenohumeral joint instability, pain associated with acromioclavicular arthropathy)
- Tendon calcification \> 0.5 cm.
- Previous shoulder surgery
- Full-thickness tear of one tendon
- Pregnant women
The study team makes the final eligibility decision.
Where it's taking place
- Angers, France
- Brest, France
- Chambray-lès-Tours, France
- Cholet, France
- La Roche-sur-Yon, France
- Le Mans, France
- Nantes, France
- Rennes, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Angers, France; Brest, France; Chambray-lès-Tours, France; Cholet, France; La Roche-sur-Yon, France; Le Mans, France and 2 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.